Analysts Set 12-Month Target Of $15 Per Share For $ENLV Thanks To High Profile Collab. Agreement

  • last year
Enlivex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on macrophage reprogramming with a goal of developing affordable, off-the-shelf cell therapies for difficult-to-treat life-threatening diseases, such as solid cancers and Sepsis, that have no good solutions today.

Recommended

0:36
I
Up next
Ulta Beauty's Earnings Miss Expectations as Same-Store Sales Decline. CEO Dave Kimbell Attributes Defends Company's Engagement and Operations.
Benzinga
0:39
Lululemon Misses Revenue Target for First Time in Two Years Amid Botched Launch. CEO Defends Brand's Strength
Benzinga
0:42
Nvidia May Invest $100 Million in OpenAI, Joining Apple and Microsoft. Massive Funding Round Could Value the AI Startup at Over $1 Billion.
Benzinga
0:40
Dell Sees 9% Revenue Boost as AI-Optimized Server Sales Surge. AI Server Backlog Hits $3.8 Billion Amid Revenue Growth
Benzinga
0:29
Former First Lady Melania Trump Opens Up About Emotional Journey of Writing Her Memoir as It Climbs up Amazon's Best Sellers List Ahead of Release Date
Benzinga
10:41
This Biotech Reprogrammes Our Own Cells To Heal The Body
Benzinga
1:14
$ENLV, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
Benzinga
9:25
Want To Be A Part Of The Fight Against CNS Cancers?
Benzinga
12:42
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer
Benzinga
10:49
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
Benzinga
10:41
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Benzinga
15:01
The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research
Benzinga
3:55
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience
Benzinga
1:31
How Elicio Therapeutics $ELTX Is Taking A Different Approach To Treating Cancers
Benzinga
9:12
Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer Conference
Benzinga
8:36
Hillstream – Drug Maker Licenses Critical New Technology In Fight Against Cancer
Benzinga
11:06
Candel Therapeutics (NASDAQ: $CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409
Benzinga
6:39
Atossa Therapeutics: This Drug Developer Is Dedicated To “Transforming The Breast Cancer Paradigm”
Benzinga
8:39
This Biotech Is Creating Targeted Radiotherapuetics For Some Of The Deadliest Cancers. Hear From Plus Therapeutics At Benzinga's Virtual Healthcare Summit
Benzinga
4:35
Mainz Biomed & Liquid Biosciences Use AI To Develop Next-Generation Colorectal Screening Test
Benzinga
1:18
CAR-T Cell Therapy Market
RenubResearch
1:52
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
Benzinga
10:36
This BioPharma Could Be First To Market With Its Celiac Therapy
Benzinga
0:58
New Cancer Treatment Method Causes Cells To 'Commit Suicide'
Geo Beats
17:49
INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease
Benzinga